Our recent perplexing findings that polyploid giant cancer cells (PGCCs) acquired embryonic-like stemness and were capable of tumor initiation raised two important unanswered questions: how do PGCCs acquire such stemness, and to which stage of normal development do PGCCs correspond. Intriguingly, formation of giant cells due to failed mitosis/cytokinesis is common in the blastomere stage of the preimplantation embryo. However, the relationship between PGCCs and giant blastomeres has never been studied. Here, we tracked the fate of single PGCCs following paclitaxel-induced mitotic failure. Morphologically, early spheroids derived from PGCCs were indistinguishable from human embryos at the blastomere, polyploid blastomere, compaction, morula and blastocyst-like stages by light, scanning electron or three-dimensional confocal scanning microscopy. Formation of PGCCs was associated with activation of senescence, while budding of daughter cells was associated with senescence escape. PGCCs showed time-and space-dependent activation of expression of the embryonic stem cell markers OCT4, NANOG, SOX2 and SSEA1 and lacked expression of Xist. PGCCs acquired mesenchymal phenotype and were capable of differentiation into all three germ layers in vitro. The embryonic-like stemness of PGCCs was associated with nuclear accumulation of YAP, a key mediator of the Hippo pathway. Spheroids derived from single PGCCs grew into a wide spectrum of human neoplasms, including germ cell tumors, highgrade and low-grade carcinomas and benign tissues. Daughter cells derived from PGCCs showed attenuated capacity for invasion and increased resistance to paclitaxel. We also observed formation of PGCCs and dedifferentiation in ovarian cancer specimens from patients treated with chemotherapy. Taken together, our findings demonstrate that PGCCs represent somatic equivalents of blastomeres, the most primitive cancer stem cells reported to date. Thus, our studies reveal an evolutionarily conserved archaic embryonic program in somatic cells that can be de-repressed for oncogenesis. Our work offers a new paradigm for cancer origin and disease relapse.
INTRODUCTION
A hallmark of many malignant tumors is dedifferentiated (immature) cells bearing little or no resemblance to the normal cells from which the cancer originated. 1 A salient feature of dedifferentiation is the presence of giant cells with multiple copies of genomic DNA, referred to as polyploid giant cancer cells (PGCCs). 2 A polyploid genome has been found in 37% of solid tumors. 3 Polyploid cells were traditionally considered senescent and induction of polyploidy was traditionally considered a tumor suppressor mechanism as polyploid cells are believed to be unable to execute mitosis. [4] [5] [6] [7] However, PGCCs have been shown to generate daughter cells via budding [8] [9] [10] [11] [12] and to contribute to immortalization, transformation and RAS-mediated tumor initiation and metastasis. [13] [14] [15] Furthermore, tetraploid cells, not diploid cells, have been shown to be the main drivers of tumorigenesis. 16, 17 In addition, development of polyploidy has been shown to favor escape from senescence in chemotherapytreated cancer cells. [18] [19] [20] However, the mechanisms by which polyploidy gives rise to malignancy remain poorly defined.
We recently reported that PGCCs are cancer stem cells that can be induced from ovarian cancer cells by the hypoxia-mimetic agent CoCl 2. 2 We showed that PGCCs from ovarian cancer can grow into tumor spheroids, initiate tumor growth in nude mice and differentiate into other benign cell types in vitro and in vivo. 2, 14, 21, 22 These properties of PGCCs were also reported in colon cancer. 23 A PGCC phenotype has recently been linked to CSL, a central node in Notch signaling. 24 We also showed that growth and division of PGCCs involves a multistep programmed process, which we refer as to the giant cell cycle, with four distinct but overlapping phases, initiation, self-renewal, termination and stability, via which PGCCs give rise to new cancer-initiating cells. 25 However, it is unclear how PGCCs acquire such stemness and which normal developmental stage PGCCs correspond to.
Polyploidy is common in plants and nonvertebrate animals but is generally incompatible with normal development of mammals except in a limited number of somatic cells or tissues. 4, 26, 27 Intriguingly, blastomeres, which are produced by cleavage of the zygote in the human preimplantation embryo, frequently display mosaicism of diploidy and polyploidy. As embryogenesis progresses, mononucleated or multinucleated giant blastomeres are commonly seen due to frequent mitosis/cytokinesis failure and endoreplication. [28] [29] [30] [31] [32] The proportion of embryos with more than five polyploid cells is 30.8% for morulae and 29.3% for blastocysts. 33 A large proportion of polyploid blastomeres (50-80%) display high levels of genomic abnormalities. [29] [30] [31] [34] [35] [36] Therefore, formation of polyploid blastomeres appears to facilitate the development of compaction and subsequent blastocysts, and mitosis/cytokinesis failure may represent a normal mechanism regulating development of the preimplantation embryo. 28, 29, 37 The similarities between PGCCs and blastomeres raise the intriguing possibility that PGCCs are somatic equivalents of blastomeres. To investigate this possibility, we tracked the development of single PGCCs derived from ovarian cancer cells treated with paclitaxel.
RESULTS
PGCCs exhibited a developmental pattern similar to that of the blastomere-like embryo The experimental design is shown in Figure 1A . Ovarian cancer cell lines Hey, SKOV3 and MDA-HGSC-1 were treated with paclitaxel overnight (16-18 h ) to induce mitotic failure. The surviving cells entered an endoreplication cell cycle, grew as PGCCs and were allowed to recover for 7 days as previously described. 25 At day 7 (spheroid day 1 (sD1)), PGCCs were collected for threedimensional (3D) culture or transferred to stem cell medium and allowed to grow as spheroids. From sD1 to sD21, spheroids were collected at different time points and fixed for immunofluorescence and immunohistochemical staining (IHC). At sD14, spheroids were reattached on cover slides and cultured with differentiation medium for an additional 14 days. At sD28, cell differentiation was evaluated via immunofluorescence and IHC.
At sD1, light microscopy showed that paclitaxel-treated Hey and SKOV3 cells grew as homogeneous PGCCs, and paclitaxel-treated MDA-HGSC-1 cells grew as spheroids with enlarged cells (Supplementary Figure 1A) . The percentage of polyploid cells was significantly higher in paclitaxel-treated than in control cells (Supplementary Figure 1B) . The percentage of senescent cells was significantly higher in PGCCs than in control cells or PGCCderived daughter cells (Supplementary Figures 1C and D) . At sD7, PGCCs showed greater spheroid-forming capacity ( Figure 1B ) but formed smaller spheroids than control cells ( Figure 1C ). Representative photos of spheroids are shown in Figure 1D .
To study the development of PGCCs, growth of single control Hey cells and Hey-derived PGCCs in stem cell medium was tracked by light microscopy. Control Hey cells formed coral-like structures within 7-14 days ( Figure 1E ). Scanning electron microscopy showed long microvilli, ruffles and filopodia on the surface of Hey cells and Hey-derived spheroids ( Figure 1F ).
In contrast, Hey-derived PGCCs showed vacuolation of the cytoplasm ( Figure 1G , white arrow). At sD3 and sD5, daughter cells budded from PGCCs asymmetrically, and at sD7 and sD14, spheroids were observed with mixed giant and small cells ( Figure 1G ). Nuclei of different sizes were found inside and on the surface of PGCCs ( Figure 1H ). Similar growth and morphology were seen in MDA-HGSC-derived PGCCs (Supplementary Figure 1E) .
To visualize ultrastructural morphology during PGCC growth, we reattached individual Hey-derived PGCCs to ultra-lowattachment plates and tracked PGCC division by scanning electron microscopy. Unexpectedly, when PGCCs started to divide, they were covered by numerous uniform microvilli and were morphologically indistinguishable from blastomeres ( Figure 1I) . 38, 39 The cleavage dividing PGCCs resembled one-cell, two-cell, three-cell, four-cell, six-cell, compaction-like and 10-to 12-cell blastomeres and morulas ( Figure 1I) , similar to what is observed in the embryoid body. 40 On 3D confocal scanning microscopy, single PGCCs formed blastocyst-like structures ( Figure 1J , Supplementary Movies 1 and 2). 3D confocal scanning images of daughter cells from PGCCs are shown in Supplementary Figure 1F and Supplementary Movie 3. We concluded that PGCCs may undergo dedifferentiation toward embryo-like structures.
PGCCs exhibited expression of embryonic stem cell markers We next performed immunofluorescence staining to determine the expression pattern of four stem cell transcription factors, OCT4, stage-specific embryonic antigen 1 (SSEA1), SOX2 and NANOG, over 14 days in Hey-derived PGCCs transferred to serumfree stem cell medium in ultra-low-attachment dishes on sD1. SSEA1 expression in PGCCs was activated on sD1, limited to the subnuclei or cytoplasm at sD7 and decreased by sD14 (Figure 2a ). OCT4 expression was activated on day sD3 and remained activated in a subset of PGCC nuclei at sD14. SOX2 expression and NANOG expression were activated on sD1 and remained activated in a subset of PGCCs at sD14.
Hematoxylin-eosin staining showed that cells in 'spheroids' derived from regular cancer cells (control spheroids) were relatively homogeneous in size (Figure 2b ). In contrast, the cells in PGCC-derived spheroids exhibited marked variation in size, and PGCC-derived spheroids had anaplastic nuclei (Figure 2b , black arrows), several cyst-like structures (middle panel) and erythrocyte-like (red arrow) and macrophage-like morphology (blue arrow), suggesting that PGCC-derived spheroids were capable of dedifferentiation in vitro.
Notably, expression of the epithelial marker cytokeratin was significantly lost in PGCC-derived spheroids compared with control spheroids (Figure 2c ), whereas expression of the mesenchymal marker fibronectin showed the opposite pattern. Consistent with the immunofluorescence results, strong OCT4 expression was found in rare cells in PGCC-derived spheroids ( Figure 2c ).
Next, we examined OCT4, NANOG, SOX2 and SOX4 expression in control spheroids and PGCC-derived spheroids from MDA-HGSC-1 cells (Figure 2d ). Expression of all three factors was increased in PGCCs. Interestingly, the budded daughter cells were also positive for SSEA1 (Figure 2d ).
Another recognized feature of embryonic stemness is loss of Xist expression, an RNA marker for inactivation of X chromosome. 41 Xist expression was lost in PGCCs derived from Hey and MDA-HGSC-1 cells and was re-acquired by PGCC-derived daughter cells (Figure 2e ), further supporting the acquisition of embryonic-like stemness in PGCCs.
At the messenger RNA (mRNA) level, expression of OCT4, NANOG and DAZL (deleted in azoospermia-like), a marker for primordial germ cell development, 42 increased in paclitaxel-treated Hey and SKOV3 cells in a time-dependent manner ( Figure 2f ). Western blotting showed that OCT4 and NANOG expression in Hey-derived PGCCs was upregulated from sD1, peaked at sD14, when PGCCs began to bud and had almost disappeared by sD21 (Figure 2g ). SOX2 expression in Hey-derived PGCCs was upregulated from sD7, peaked at sD14 and then slightly decreased sD21, when the daughter cells start to appear. Similar patterns of expression were observed in SKOV3-derived PGCCs.
Examination of expression of cancer stem cell markers ALDH1, CD133 and CD117 using fluorescence-activated cell sorting showed that ALDH1-FITC expression was higher in Hey-derived PGCCs than in regular cancer cells ( Supplementary Figures 2A and B) . No CD133 or CD117 expression was detected in Hey-derived PGCCs or regular cancer cells (Supplementary Figure 2C) , suggesting that expression of cancer stem markers is associate with formation of PGCCs.
PGCCs can differentiate into three germ layers in vitro To further determine the nature of PGCC-mediated stemness, we examined the phenotype of PGCCs following paclitaxel treatment. The cultures displayed mixtures of PGCCs and budded daughter cells of various morphologies ( Figure 3A) , including epitheliumlike ( Figure 3A(b) ), fibroblast-like ( Figure 3A(c) ), mixed epithelial and mesenchymal ( Figure 3A Next, we investigated the kinetics of activation of expression of alpha fetal protein (AFP), smooth muscle actin (SMA) and β3-tubulin (also known as PAX6), markers for endoderm, mesoderm and ectoderm, respectively, in Hey and SKOV3 cells. In Hey cells, mRNA levels of AFP and SMA were increased starting on day 1 of paclitaxel treatment, peaked at day 21 and decreased at day 28, by which time PGCC-derived daughter cells had formed ( Figure 3B ). In contrast, the mRNA levels of PAX6 remained relatively unchanged over this period. The protein levels of these three markers were much higher in Hey-derived PGCCs than in regular Hey cells and higher in daughter cells than in regular Hey cells ( Figure 3C ). SMA and β3-tubulin protein levels were higher in SKOV3-derived PGCCs than in regular SKOV3 cells and daughter cells ( Figure 3C ). However, there was no change in AFP expression at the mRNA or protein level in SKOV3 cells, suggesting that AFP expression may be cell line specific.
We then examined the ability of Hey-derived PGCCs to differentiate. In PGCC-derived spheroids but not in regular Hey cells, oil red staining, a marker of adipose differentiation, was observed when spheroids were cultured in adipogenesis medium ( Figure 3D ); blue drops indicating sulfate chondroitin, a marker of chondrogenesis, were observed when spheroids were cultured in chondrogenesis medium ( Figure 3E ); and scale-like osteogeninpositive signals were observed when spheroids were cultured in osteogenesis medium ( Figure 3F ). Expression of AFP, SMA and β3-tubulin was detected when spheroids were cultured in stem cell medium ( Figure 3G ).
When Hey cells were cultured on a scaffold membrane, PGCCs grew mainly on the membrane surface as normal fallopian-tubelike epithelial cells, the known origin of high-grade serous carcinoma, 43 whereas regular Hey cells invaded into the membrane ( Figure 3H ). These findings demonstrated that PGCCs were capable of growing back into the normal cell of origin of ovarian cancer.
Differentiation capability of PGCCs depends on nuclear location of YAP YAP, a critical Hippo pathway protein, is involved in the regulation of stem cells and cancer development and is responsible for cytokinesis-failure-induced activation of tumor suppressor pathway. 44, 45 We examined the role of YAP in the regulation of stemness and differentiation of PGCCs. YAP was located mainly in the cytoplasm of regular Hey cells and daughter cells but predominantly in the nuclei of PGCCs (Figures 4a and b) . Treatment of PGCCs with dobutamine, which inhibits YAP nuclear translocation, abolished nuclear localization of YAP (Figure 4a (Figure 4d , upper panels), and again, dobutamine inhibited this differentiation (Figure 4d , lower panels). GATA6, a key regulator in generation of primitive endoderm, 46 was also activated in PGCCs induced by paclitaxel or CoCl 2 (Supplementary Figure 3A) , suggesting that GATA6 may be a critical mediator for early embryonic-like development in somatic cells, similar to that in the embryo. We also observed endoderm differentiation of PGCCs induced by CoCl 2 (Supplementary Figure 3B) .
PGCC-derived spheroids transform into mixed germ cell tumors and carcinoma of different grades in vivo
To determine the nature of tumors that developed from PGCCderived spheroids in vivo, we injected green fluorescence protein (GFP)-ubiquitin-labeled control Hey-cell-derived spheroids (10 000 cells) and PGCC-derived spheroids (1000 cells) collected at sD7 into the subcutis or testis of SCID (severe combined immunodeficiency) mice. All the tested spheroids formed subcutaneous or testis tumors, but PGCC-derived spheroids took significantly longer to form 1 cm tumors (60-120 days vs 30 days).
Control Hey-cell-derived spheroids formed high-grade carcinomas ( Figure 5A(a) ). In contrast, PGCC-derived spheroids formed a spectrum of tumors, including mixed germ cell tumor composed of dysgerminoma and embryonic carcinoma ( Figures 5A(b) and A(c)), dysgerminoma with skeletal muscle differentiation ( Figure 5A (d)), embryonic carcinoma ( Figures 5A(e) and B(g), embryonic carcinoma transitioned into mesenchymal morphology ( Figure 5A (f)), high-grade carcinoma ( Figure 5A(g) ), mixed high-grade and lowgrade carcinoma ( Figure 5A(h) ) and benign squamous cells ( Figure 5A(i) ). Mixed germ cell tumors were observed in (19%) mice with subcutaneous and intratesticular injections (20%) and no tumors in the control groups (Po0.0001; Table 1 ).
To further determine the level of maturation of germ cells, we performed IHC on continuous sections. Carcinoma from control cells showed high-grade morphology, weak expression of keratin and no expression of germ cell markers SALL4 and OCT4 ( Figure 5B ). Dysgerminoma and embryonic carcinoma from PGCC-derived spheroids showed SALL4 staining but different levels of epithelial maturation as reflected in different intensities of cytokeratin and OCT4 staining ( Figure 5B ). Results of additional IHC to characterize the germ cell tumor are shown in Supplementary Figures 4A and B . We also demonstrated that germ cell tumors were derived from human, not mice, using GFPubiquitin-labeled cancer cells (Supplementary Figure 4C) .
The above findings suggested that PGCCs were capable of differentiation into primordial germ cells and a wide spectrum of epithelial neoplasms from high-grade to benign tumors.
PGCC-derived daughter cells acquire drug resistance and mesenchymal features To determine whether PGCC-derived daughter cells differ from parental regular cancer cells, we first analyzed the apoptotic response and sensitivity to paclitaxel. Untreated daughter cells had more polyploid cells than regular cells did (Figure 6a) . Following paclitaxel treatment, the total apoptotic percentage (Q2 +Q4) was lower in daughter cells than regular cells (Figure 6b ). The IC50 values for paclitaxel and vincristine were significantly higher for daughter cells than for regular cells, but the IC50 values for olaparib and topotecan did not differ between the two cell types (Figure 6c, Supplementary Table 2 ), demonstrating that paclitaxelinduced PGCCs can generate daughter cells chemoresistant not only to paclitaxel but also to other drugs.
The daughter cells were less invasive than the regular cancer cells (Figures 6d and e) . Both PGCCs and daughter cells displayed increased expression of pan-cytokeratin, mesenchymal markers vimentin, fibronectin and N-cadherin, and epithelial-mesenchymal transition regulatory transcription factors Snail, Slug and Twist 2 and decreased expression of β-catenin (Figure 6f ). Morphologic features of epithelial-mesenchymal transition were also observed in xenografts (Figure 6g ). Tumors from regular cancer cells grew faster than tumors from PGCC-derived daughter cells (Figure 6g) . The regular cancer-cell-derived tumors had predominantly epithelial cell morphology, whereas the daughter-cell-derived tumors had mesenchymal-shaped cells with increased heterogeneity (Figure 6g ), suggesting that decreased proliferation together with acquired ability to differentiate via epithelial-mesenchymal transition confers acquired resistance to paclitaxel in daughter cells.
Formation of PGCCs and dedifferentiation of ovarian cancer after chemotherapy We reasoned that we should be able to observe dedifferentiation following chemotherapy in ovarian cancers in patients. Toward this end, we examined paired specimens of human ovarian cancer obtained before and after chemotherapy. Although the prechemotherapy specimens had relatively homogeneous cells, the post-chemotherapy specimens had increased numbers of anaplastic PGCCs with marked variation in size and large bizarre nuclei ( Figures 7A and B) . Post-chemotherapy specimens had small daughter cells budded off from a single PGCC (Figures 7B and C, black arrow) and erythrocyte-like cells within the cytoplasm of PGCCs (Figures 7Bd, blue arrow) . The nuclear area of budded daughter cells was significantly smaller than that of prechemotherapy cancer cells ( Figure 7D ).
After chemotherapy, 3 of 38 samples were positive for OCT4 (in cytoplasm and nuclei), 12 of 38 were positive for NANOG (mainly in cytoplasm) and 17 of 38 were positive for SOX2 (mainly in (H) 3D culture of regular Hey cells and PGCCs (at sD1) in the Alvetex scaffold system for 7 days. Regular Hey cells penetrated into the scaffold membrane, while PGCCs mainly grew on the surface of the membrane and formed a monolayer epithelial-like structure (hematoxylin-eosin (H&E) staining). Human-specific cytokeratin (CK) positivity confirmed the epithelium source. nuclei); before chemotherapy, no cases were positive for OCT4 or NANOG, and only 2 of 38 were positive for SOX2 (mainly in the cytoplasm; Figure 7E ). Nuclear localization of YAP was observed in the three cases of post-chemotherapy not in pre-chemotherapy control ( Figure 7E ). These findings demonstrated that treated cancer cells showed increased expression of embryonic stem cell markers in a subset of post-chemotherapy treated ovarian cancers.
Xist expression is generally associated with differentiated state of somatic cells. 41 We examined Xist expression in regular cancer cells and PGCCs. Xist was strongly expressed in nuclei of cancer and stromal cells before chemotherapy but was largely lost in nuclei of PGCCs after chemotherapy ( Figure 7F ), further supporting the concept that PGCCs acquired embryonic-like stemness.
DISCUSSION
In this work, we demonstrated that PGCCs are the somatic equivalent of blastomeres. This study validated our early reports that showed embryonic-like stemness of PGCCs. 2, 14, 21, 22 By using CoCl 2 to induce hypoxia or paclitaxel to induce mitotic failure, we showed that PGCCs acquired the properties of blastomeres, including differentiation into three germ layers and formation of germ cell tumors and carcinoma of different grades as well as benign tissue, similar to what have traditionally been referred as teratocarcinomas except that the tumors described here were generated via reprogramming from epithelial carcinoma cells. 47, 48 To our knowledge, PGCCs are the most primitive induced cancer stem cells reported to date.
The embryonic origin of cancer was proposed as early as the late nineteenth century by Cohnheim in 1867. 49 However, direct experimental evidence for an embryonic origin of cancer was lacking until Stevens demonstrated in 1964 that the embryonic stem cells from murine blastocysts could develop into teratoma/ teratocarcinoma; 50, 51 and Pierce demonstrated in the same year that single embryonic carcinoma cells could generate multiple lineages of benign cells 52 and in 1971 that carcinoma can generate benign cells. 53 This work led Pierce to propose that tumors are caricatures of the process of tissue renewal and maturation arrest. 54, 55 These early experiments clearly linked embryogenesis, tissue differentiation and tumor initiation.
More recently, the work of Nobel laureates Gurdon and Yamanaca and others has made clear that much development is a bidirectional process. [56] [57] [58] The tumorigenicity of both embryonic stem cells and induced pluripotent stem cells is well known. 59, 60 Just as maturation arrest of differentiation can lead to tumor development, incomplete reprogramming can lead to tumor development, 61 activation of embryonic program has also been shown in irradiation treated tumor cells. 62 although it remains unknown whether there is an endogenous pathway capable of activating an embryonic program in somatic cells. Our findings reported here demonstrate that PGCCs may be a missing link that can lead to de-repression of a repressed embryonic program in somatic cancer cells for drug resistance and disease relapse.
Our findings above and in our previous publications 2, 21, 22, 25 prompted us to conceptualize a blastomere model for tumorigenesis and disease relapse. In normal preimplantation embryonic development ( Figure 8A ), after fertilization, the zygote undergoes cleavage division to generate a two-and four-cell blastomere, which can grow into polyploid blastomeres because of increased mitosis/cytokinesis failure, which undergo compaction and then develop into a morula and blastocyst. Differentiation into the inner cell mass and trophectoderm then occurs, followed by cell sorting into the primitive endoderm and pluripotent epiblasts and then gastrulation to form the three germ layers and germ cells. The stem cells differentiate along specific levels of the developmental hierarchy and become restricted to specific cell types. Maturation arrest due to genetic/epigenetic mutations acquired in embryo or later in life (M' for germ cells; M1 to M4 for somatic cells) at the different levels of the developmental hierarchy generates tumors of different grades of malignancy, a phenomenon referred to as Pierce maturation arrest. 55 Similarly, somatic cells can enter blastomere-like development by switching mitosis to endoreplication ( Figure 8B ) via the giant cell cycle that we recently described. 25 During the initiation phase of the giant cell cycle, failed mitosis/cytokinesis activates endoreplication, by which cells can escape senescence/apoptosis. During the self-renewal phase, the polyploid cells grow autonomously and develop into compaction-, morula-and blastocyst-like embryos and generate inner cell-mass-like stem cells. During the termination phase, polyploid growth ends and the inner cell-masslike stem cells bud small embryonic-like stem cells. During the stability phase, these stem cells with acquired genetic/epigenetic mutations that arrested at different developmental hierarchies (a', b', c' and d') will gradually acquire competence in mitosis, achieve stable diploid karyotype and grow into tumors of different grades, including germ cell tumors. The level of dedifferentiation varies according to the type of stressors and duration of stress and the cell type: the longer the giant cell cycle, the closer the resulting cells to the primitive stage and the greater level of their developmental potential for different grades as well as types of tumors.
Our findings also provide new insights into chemotherapy resistance. Paclitaxel is a microtubule poison; 63 its therapeutic effects are largely due to arrest of cells at mitosis, which leads to mitotic catastrophe and cancer cell death via apoptosis or necrosis or chromosomal missegregation. 64, 65 However, resistance to paclitaxel is common in patients. Polyploidy has recently been proposed to be the main cause of docetaxel resistance. 66 Our studies provide strong experimental evidence supporting a central role of polyploidy in drug resistance by providing most primitive cancer stem cells for drug resistance and disease relapse.
In summary, our findings constitute strong experimental evidence that PGCCs function as blastomere-like stem cells to facilitate the neoplastic evolution in response to various genetic/ epigenetic or environmental stressors. Blocking formation of polyploidy and redirecting differentiation of PGCCs toward benign lineages may be promising therapeutic approaches for cancer.
MATERIALS AND METHODS

Cell lines, cell labeling, PGCC formation and clinical specimens
Human ovarian cancer cell lines Hey and SKOV3 were recently described. 25 MDA-HGSC-1, MD Anderson high-grade serous carcinoma cell line 1 (ID 2414), was established from a patient-derived xenograft from high-grade ovarian serous carcinoma. This line grew as spheroids in low-attachment dishes in modified medium (WIT/NoE, 1:1). The Hey cells were labeled with ubiquitin-enhanced GFP (FG12) as described previously. 25 At 60-70% PGCCs represent somatic equivalents of blastomeres N Niu et al confluence, the cells were treated with paclitaxel (500 nM, Sigma, St Louis, MO, USA) overnight (16-18 h) ; the cells were then allowed to recover for 7 days to form PGCCs. Thirty-eight paired samples of archived, paraffin-embedded high-grade ovarian serous carcinoma obtained before and after six cycles of paclitaxeland carboplatin-based chemotherapy were subjected to histology analysis and IHC for different markers. Use of these samples was approved by MD Anderson's Institutional Review Board.
Spheroid formation
At recovery day 7 after paclitaxel treatment, PGCCs were dissociated and cultured with FBS-free stem cell medium (Gibco, Grand island, NY, USA) in low-attachment plates (Corning, Corning, NY, USA). A total of 5000 test cells in 3 ml of stem cell medium were cultured in 60 mm low-attachment dishes. Spheroid formation was then observed for an additional 14 days. Spheroids more than 100 μm in diameter were counted. Spheroids were also grown from PGCCs induced by CoCl 2 as previously described; 2 these spheroids were used to study endoderm differentiation.
Hematoxylin-eosin staining, immunohistochemistry and immunofluorescence
Hematoxylin-eosin staining, IHC and single and double immunofluorescence labeling were performed as described previously 2 . Primary antibodies are listed in Supplementary Table 1. β-Gal staining β-Gal staining for senescence was performed as described previously. 67 
Western blot analysis
Western blot analysis was performed as described previously. 68 Scanning electron microscopy Attached PGCCs, spheroids and control regular cancer cells were examined with scanning electron microscopy as previously described. 69 Live 3D confocal scanning of early-stage PGCC-derived spheroids GFP-ubiquitin-labeled Hey cells were treated with paclitaxel, allowed to recover in regular medium for 7 days, and then cultured with stem cell medium for 2 days. The cells and spheroids were stained with Hoechst 33342 and multiply scanned at XY axis along the Z direction; images were reconstructed with a Carl Zeiss 710 confocal microscope (Zeiss, Thornwood, NY, USA).
Xist RNA in situ hybridization An RNAscope immunofluorescence kit (Advanced Cell Diagnostics, Hayward, CA, USA) was used on fixed cells on coverslips and an RNAscope 
Analysis of stemness and differentiation capacity of PGCCs
PGCCs were cultured with stem cell medium for 7 days, reattached on coverslips and cultured on Matrigel (Corning)-coated coverslips with specific differentiation media (Gibco: adipogenesis, chondrogenesis and osteogenesis differentiation media; Stem Cell Technologies (Cambridge, MA, USA): endoderm differentiation, astrocyte-inducing, differentiation and mature media) according to the manufacturers' protocols. Dobutamine (10 μM) was used to block the nuclear accumulation of YAP. The cells were then fixed with 10% paraformaldehyde/PBS for immunofluorescence staining.
Oil red staining for fat vacuoles was performed with a lipid staining kit (Zenbio, Research Triangle Park, NC, USA) and Alcian blue staining for chondroitin was performed with an Alcian blue pH 2.5 periodic acid-Schiff staining kit (Fisher Scientific, New Kensington, PA, USA) according to the manufacturer's protocol. Immunofluorescence staining against osteogenin, AFP, CXCR4, c-Kit, YAP, GFAP, CD133, SMA and β3-tubulin was performed as described previously. 70 Primary antibodies are listed in Supplementary Table 1 .
Flow cytometry ALDH1-FITC, CD133-PE and CD117-APC were incubated with Hey-derived PGCCs at recovery day 7 (sD1) and analyzed by a FACS Canto II flow cytometer (BD Biosciences, San Jose, CA, USA). The ovarian cancer cells stained with propidium iodide (Sigma) were also analyzed by a FACS Canto II flow cytometer.
Invasion analysis and 3D culture
Invasion assay was performed in a matrigel invasion chamber (BD Biosciences, Bedford, MA, USA) according to the manufacturer's protocol. The 3D spatial structure of control and PGCC-derived spheroids was determined with an Alvetex scaffold system (AMS Biotechnology, Cambridge, MA, USA) according to the manufacturer's protocol.
Reverse transcription and real-time quantitative PCR Total RNA from PGCCs at different time points (days 1, 3, 7, 14, 21, 28) was extracted and purified using an RNeasy Kit (Qiagen, Dusseldorf, Germany); 1 μg of total RNA was used for reverse transcription with Iscript Reverse Transcription Supermix (Bio-Rad, Hercules, CA, USA), and qPCR reactions were performed in PGCCs, which grow into blastomere-like (BM-like), compaction-like and morula-like cell masses (self-renewal) and then differentiate into structures morphologically similar to the blastocyst with inner cell mass and then into the three germ layers and germ cell lineage (termination). The entire process mimics development of preimplantation embryo via the giant cell cycle (preimplantation-like). The germ cells and primitive stem cells arrest at different developmental hierarchies to generate germ cell tumors (GCTs) and somatic tumors with different levels of malignancy. a′, b′, c′ and d′ correspond to levels of developmental hierarchy following stress-induced reprogramming.
triplicate as described previously. 70 The primers for OCT4, NANOG, DAZL, AFP, SMA and PAX6 were designed as described previously. 71, 72 Changes in gene expression were calculated by using the ΔΔCt method.
Tumorigenesis in mice from spheroids or daughter cells derived from single PGCCs Spheroids derived from single PGCCs and control cells were cultured in stem cell medium for 7 days. For testis injection, single spheroids in 10 μl of PBS were injected one spheroid per mouse into the testis of male SCID mice 2 months of age (16 injections) and controls (eight mice). Daughter cells from single PGCC-derived colonies were isolated and passaged for more than 10 generations to obtain stable populations. Then 10 4 daughter or control cancer cells in 50 μl of PBS and 50 μl of Matrigel (Corning) were injected subcutaneously into the SCID mice. When tumors reached 1 cm, the mice were killed, and the tumor nodules were harvested for histology and IHC. Tumor types were diagnosed by two pathologists (JL and NN). The primary antibodies are listed in Supplementary Table 1 . The use and care of mice were approved by the MD Anderson's Institutional Animal Care and Use Committee.
